Defining the Role of Lipoprotein Apheresis in the Management of Familial Hypercholesterolemia

Author： >   Datta Borunendra N.   >   Rees Alan   Halcox Julian  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.11, Iss.6, 2011-12, pp. : 363-370

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

By Vogt Anja   Parhofer Klaus G  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 691-697

Informa Healthcare

Access to resources Recommend Favorite

New therapies for familial hypercholesterolemia

By Burnett John R   Watts Gerald F  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 3, 2006-03 ,pp. : 349-361

Informa Healthcare

Access to resources Recommend Favorite

Apolipoprotein polymorphisms and familial hypercholesterolemia

By Dedoussis George VZ  

Pharmacogenomics, Vol. 8, Iss. 9, 2007-09 ,pp. : 1179-1189

Future Medicine

Access to resources Recommend Favorite

Gene Therapy for Familial Hypercholesterolemia

By  

Current Pharmaceutical Design, Vol. 17, Iss. 24, 2011-08 ,pp. : 2575-2591

Bentham Science Publishers

Access to resources Recommend Favorite

Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits - a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia

By Napoli C.   Cicala C.   D'Armiento F.P.   Roviezzo F.   Somma P.   de Nigris F.   Zuliani P.   Bucci M.   Aleotti L.   Casini A.   Franconi F.   Cirino G.  

General Pharmacology, Vol. 33, Iss. 6, 1999-12 ,pp. : 467-477

Elsevier

Access to resources Recommend Favorite